Kyverna Therapeutics (KYTX) Capital Expenditures (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Capital Expenditures of $5000.0 for Q1 2026, down 99.55% on a QoQ basis from $1.1 million in Q4 2025, and down 99.03% year-over-year from $515000.0 in Q1 2025.
Kyverna Therapeutics (KYTX) Capital Expenditures (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $5000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 99.03% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $618000.0 (down 74.04% YoY) and the FY2025 annual result came in at $1.1 million, down 42.3% from the prior year.
- Capital Expenditures was $5000.0 for Q1 2026 at Kyverna Therapeutics, down from $1.1 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.6 million in Q4 2023 and bottomed at -$499000.0 in Q3 2025.
- A 4-year average of $379769.2 and a median of $89000.0 in 2024 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 478.65% in 2025, while the deepest fall reached 150.15% in 2025.
- Kyverna Therapeutics' Capital Expenditures stood at $1.6 million in 2023, then slumped by 38.54% to $960000.0 in 2024, then climbed by 16.88% to $1.1 million in 2025, then sank by 99.55% to $5000.0 in 2026.
- Business Quant data shows KYTX's Capital Expenditures at $5000.0 in Q1 2026, $1.1 million in Q4 2025, and -$499000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 1.12 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | -499,000.00 |
| Sep 30, 2025 | -499,000.00 |
| Jun 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -10,000.00 |
| Mar 31, 2025 | 515,000.00 |
| Mar 31, 2025 | 515,000.00 |
| Dec 31, 2024 | 960,000.00 |
| Dec 31, 2024 | 960,000.00 |
| Sep 30, 2024 | 995,000.00 |
| Sep 30, 2024 | 995,000.00 |
| Jun 30, 2024 | -89,000.00 |
| Jun 30, 2024 | -89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 1.56 Mn |
| Dec 31, 2023 | 1.56 Mn |